ArrowArtboardCreated with Sketch.Title ChevronTitle ChevronEye IconIcon FacebookIcon LinkedinIcon Mail ContactPath LayerIcon MailMenu BurgerPositive ArrowIcon PrintIcon SearchSite TitleTitle ChevronIcon Twitter
Health Technology

Dr. Reddy's Laboratories Ltd.

  • 2,670.00 INR
  • +58.05
  • +2.22%
  • India
    Jul 19, 2019
  • Ticker
    BOM(500124)
  • Prev. close
    2,611.95
  • Market cap (INR)
    433,727.21M
  • Market cap (USD)
    6,303.54M
  • Shares
    166.05M

Business Summary

Dr. Reddy's Laboratories Ltd. engages in the manufacture and marketing of pharmaceutical products. It operates through the following segments: Global Generics, Pharmaceutical Services and Active Ingredients, Proprietary Products, and Others. The Global Generics segment consists of manufacturing and marketing of prescription and over-the-counter finished pharmaceutical products ready for consumption by the patient, marketed under a brand name or as generic finished dosages with therapeutic equivalence to branded formulations. The Pharmaceutical Services and Active Ingredients segment is comprised of manufacturing and marketing of active pharmaceutical ingredients and intermediates, also known as API or bulk drugs, which are principal ingredients for finished pharmaceutical products. The Proprietary Products segment focuses on research, development, and manufacture of differentiated formulations and new chemical entities. The Others segment includes the operations of the wholly-owned subsidiary of the company, Aurigene Discovery Technologies Limited, a discovery stage biotechnology company developing novel and best-in-class therapies in the fields of oncology and inflammation and which works with pharmaceutical and biotechnology companies in early-stage collaborations, brining drug candidates for pre-clinical development. The company was founded by Kallam Anji Reddy on February 24, 1984 and is headquartered in Hyderabad, India.

Financial Highlights

Mar 2019 INRUSD
Revenue153,851M2,199.67M
Gross Profit78,008M1,115.31M
Operating income19,584M280.00M
Income before tax22,005M314.61M
Net income18,795M268.71M
EBITDA31,774M454.28M
Diluted EPS113.091.61
Dividends Per Share200.28
Total Assets225,427M3,254.08M
Total liabilities85,230M1,230.31M
Total equity140,197M2,023.77M
Operating cash flow27,878M398.58M
Currency in INRCurrency in USD

Historical Data

 Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019
Revenue 148,189M 154,708M 140,809M 142,028M 153,851M
Gross Profit 81,457M 87,272M 73,531M 71,189M 78,008M
Operating income 25,878M 28,806M 12,878M 11,182M 19,584M
Income before tax 27,968M 26,911M 14,304M 13,997M 22,005M
Net income 22,179M 20,013M 12,039M 9,806M 18,795M
EBITDA 33,978M 39,056M 24,155M 22,892M 31,774M
Diluted EPS 129.75 116.99 72.09 59.01 113.09
Dividends Per Share 20 20 20 20 20
Total Assets 194,762M 207,650M 219,821M 225,604M 225,427M
Total liabilities 83,460M 79,314M 95,777M 99,144M 85,230M
Total equity 111,302M 128,336M 124,044M 126,460M 140,197M
Operating cash flow 24,760M 41,613M 21,216M 17,110M 27,878M
 Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019
Revenue 2,423.62M 2,363.00M 2,099.83M 2,203.14M 2,199.67M
Gross Profit 1,332.22M 1,332.99M 1,096.54M 1,104.28M 1,115.31M
Operating income 423.23M 439.98M 192.04M 173.45M 280.00M
Income before tax 457.41M 411.03M 213.31M 217.12M 314.61M
Net income 362.73M 305.67M 179.53M 152.11M 268.71M
EBITDA 555.70M 596.54M 360.21M 355.10M 454.28M
Diluted EPS 2.12 1.78 1.07 0.91 1.61
Dividends Per Share 0.32 0.30 0.29 0.31 0.28
Total Assets 3,112.14M 3,135.64M 3,385.24M 3,459.03M 3,254.08M
Total liabilities 1,333.62M 1,197.68M 1,474.96M 1,520.10M 1,230.31M
Total equity 1,778.51M 1,937.95M 1,910.27M 1,938.92M 2,023.77M
Operating cash flow 404.94M 635.59M 316.38M 265.41M 398.58M

Valuation Measures

Mar 2019
PER24.48
ROA8.33%
ROE14.09%
Operating margin12.72%
Profit margin12.21%

Key executives

  • Co-Chairman, Chief Executive Officer & MD: Gunupati Venkateswara Prasad
  • President, CFO & Global Head-IT: Saumen Chakraborty
  • Chief Operating Officer & Global Head-Generics: Erez Israeli
  • Secretary & Compliance Officer: Sandeep Poddar
  • Executive Vice President & Head-Branded Markets: M. V. Ramana

Shareholders

  • Dr. Reddy's Holdings Ltd. (24.8%)
  • Colonial First State Asset Management (Australia) Ltd. (7.7%)
  • Life Insurance Corp. of India (3.9%)
  • First State Investment Management (UK) Ltd. (2.4%)
  • BlackRock Fund Advisors (2.1%)
  • Aditya Birla Sun Life AMC Ltd. (1.5%)
  • SBI Funds Management Pvt Ltd. (1.3%)
  • Franklin Templeton Asset Management (India) Pvt Ltd. (1.3%)
  • The Vanguard Group, Inc. (1.2%)
  • ICICI Prudential Life Insurance Co. Ltd. (Invt Port) (1.1%)

Contact Details

  • Website:http://www.drreddys.com
  • Address: Door No. 8-2-337, Road No. 3, Hyderabad, 500034, India
  • Phone: +91.40.49002900

Related Companies

  • Dr. Reddy's Laboratories Ltd. /API Manufacturing Bus/
  • Dr. Reddy's New Zealand Ltd.
  • Imperial Credit Pvt Ltd.
  • Ducere Pharma LLC/Otc Bus/
  • UCB SA /Established Product Bus/
  • Dr. Reddy's Laboratories SA
  • Dr. Reddy's Laboratories Ltd. (Russia)
  • Zenovus Biotech Pvt Ltd.
  • Reddy Holding GmbH
  • Dr. Reddy's Pharma SEZ Ltd.
  • Dr. Reddy's Bio-Sciences Ltd.
  • Promius Pharma LLC
  • Industrias Quimicas Falcon de Mexico SA de CV
  • Dr. Reddy's Laboratories (UK) Ltd.
  • Kunshan Rotam Reddy Pharmaceutical Co. Ltd.
  • Perlecan Pharma Pvt Ltd.
  • Macred India Pvt Ltd.
  • BASF SE /Pharmaceutical Contract Manufacturing Unit/
  • Reddy Pharma Italia SpA
  • Dowpharma /Small Molecules Business/
  • Dr. Reddy's Laboratories, Inc.
  • Laboratorios Litaphar SA
  • F. Hoffmann-La Roche Ltd. /Drug Ingredient Making Plant/
  • Trigenesis Therapeutics, Inc.
  • betapharm Arzneimittel GmbH
  • OctoPlus N.V.
  • Dr. Reddy's Laboratories (EU) Ltd

Competitors

  • Perrigo Co. Plc
  • Sun Pharmaceutical Industries Limited
  • Novartis AG
  • Pfizer Inc.
  • Mylan N.V.
  • KRKA dd
  • Lupin Limited
  • Cipla Limited
  • Teva Pharmaceutical Industries Limited
  • Sanofi
  • Takeda Pharmaceutical Co. Ltd.
  • GlaxoSmithKline Pharmaceuticals Limited
  • Pfizer Limited
  • Chemical Works of Gedeon Richter Plc
  • Bayer AG
  • Fresenius SE & Co. KGaA
  • STADA Arzneimittel AG
  • Alkem Laboratories Ltd.
  • Cadila Healthcare Limited
  • Endo International Plc
  • Sanofi India Limited
  • Abbott India Limited
  • Piramal Enterprises Ltd.
  • Cambrex Corporation
  • Lonza Group AG
  • Aurobindo Pharma Ltd
  • Catalent Inc
  • Dishman Carbogen Amcis Ltd.
  • GlaxoSmithkline Consumer Healthcare Ltd
  • Thermo Fisher Scientific Inc.
Last Updated on 19 Jul, 2019

You have {{numberArticlesLeft}} free article{{numberArticlesLeft-plural}} left this monthThis is your last free article this month

Stay ahead with our exclusives on Asia;
the most dynamic market in the world.

Stay ahead with our exclusives on Asia

Get trusted insights from experts within Asia itself.

Get trusted insights from experts
within Asia itself.

Get Unlimited access

You have {{numberArticlesLeft}} free article{{numberArticlesLeft-plural}} left this month

This is your last free article this month

Stay ahead with our exclusives on Asia; the most
dynamic market in the world
.

Get trusted insights from experts
within Asia itself.

Try 3 months for $9

Offer ends June 30th

Your trial period has expired

You need a subscription to...

  • Read all stories with unlimited access
  • Use our mobile and tablet apps
See all offers and subscribe

Your full access to the Nikkei Asian Review has expired

You need a subscription to:

  • Read all stories with unlimited access
  • Use our mobile and tablet apps
See all offers
NAR on print phone, device, and tablet media